TREML2/TLT-2 Antibody [Alexa Fluor™ Plus 405]

• Reactivity: Hu
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor Plus 405

TREML2/TLT-2 Antibody [Alexa Fluor™ Plus 405] Summary

• Specificity: Detects human TREML2 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross‑reactivity with recombinant mouse TREML2 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TREML2/TLT-2 Antibody [Alexa Fluor™ Plus 405]

• C6orf76
• dJ238O23.1
• FLJ13693
• MGC149715
• MGC149716
• TLT2
• TLT-2
• TREML2
• trem-like transcript 2 protein
• triggering receptor expressed on myeloid cells-like 2
• triggering receptor expressed on myeloid cells-like protein 2
• UNQ6268/PRO20473

Background

Trem-like transcript 2 protein (TLT-2; also TREML2) is a 33 kDa (unglycosylated) type I transmembrane cell surface receptor and member of the Trem family of receptor proteins.  Human TLT-2 is synthesized as a 321 amino acid (aa) precursor that contains an18 aa signal sequence, a 250 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 32 aa cytoplasmic tail (SwissProt #: Q5T2D2). Within the ECD are an Ig-like V-type domain (aa 20-121) and one potential site of N-linked glycosylation. Mature human TLT-2 shares 49% aa sequence identity with mature mouse TLT-2. Cell surface expression of TLT-2 is seen for most of the B and myeloid cell lines (1, 2). TLT-2 is also expressed constitutively on CD8⁺ T cells and induced on CD4⁺ T cells after activation (2). TLT-2 plays a role in the innate and adaptive immune responses. In 2008, Hashiguchi et al. discovered that the B7 family member B7-H3, which also plays important roles in immune responses, specifically bound to TLT-2. According to their research, stimulation with B7-H3 transfectants preferentially up-regulated the proliferation and IFN-gamma production on CD8⁺ T cells (2). Also, transduction of TLT-2 into T cells resulted in enhanced IL-2 and IFN-gamma production via interactions with B7-H3, and blockade of the B7-H3:TLT-2 pathway with mAb against B7-H3 or TLT-2 efficiently inhibited contact hypersensitivity responses (2). In 2009, however, Leitner et al. extensively analyzed interaction of B7-H3 with TLT-2 and found no evidence for such an interaction (3).

1. King, R.G. et al., 2006, J. Immunol. 176:6012.
2. Hashiguchi, M. et al., 2008, Proc. Natl. Acad. Sci. USA 105:10495.
3. Leitner, J. et al., 2009, Eur. J. Immunol. 39:1754.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.